KRSNAA · Healthcare · Diagnostics & Research
Composite scorecard: 48/100 — Quality 55 · Valuation 68 · Momentum 0
| Share price | ₹546.65 |
| Market cap | ₹1,806 Cr |
| P/E ratio | 18.0 |
| P/B ratio | 1.8 |
| ROCE | 10.6% |
| Dividend yield | 0.49% |
| Book value | ₹302.21 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹773 Cr | ₹101 Cr | 27.0% |
| 2025 | ₹717 Cr | ₹78 Cr | 27.0% |
| 2024 | ₹620 Cr | ₹57 Cr | 23.0% |
| 2023 | ₹487 Cr | ₹62 Cr | 25.0% |
| 2022 | ₹455 Cr | ₹68 Cr | 29.0% |
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clien